-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cellular immunotherapy for cancer is a therapy in which normal or bioengineered human cells are transplanted or transferred into the body of cancer patients to achieve the effect of cancer treatment
Recently, IQVIA, a world-renowned medical industry consulting company, and the non-profit organization Cancer Research Institute (CRI) published an analyst report titled The clinical pipeline for cancer cell therapies in Nature Reviews Drug Discovery, a subsidiary of Nature, describing It shows the current global clinical research and development picture of cancer cell immunotherapy
CAR-T therapy is still the mainstream, and the application of allogeneic cells is growing rapidly
CAR-T therapy is still the mainstream, and the application of allogeneic cells is growing rapidlyThe main types of cellular immunotherapy include CAR-T, TCR-transduced T cells (TCR-T), tumor infiltrating lymphocytes (TIL) and natural killer (NK) cells, etc.
Picture from Frost & Sullivan analysis
Picture from Frost & Sullivan analysisFrom this report, the global cell therapy pipeline is steadily advancing.
Comparison of cell therapies at different clinical stages from 2019 to 2021
Comparison of cell therapies at different clinical stages from 2019 to 2021Among more than 2,000 cell therapies, CAR-T is still the mainstream, with 299 new clinical pipelines, an increase of 35% over 2020, and most (80%) pipelines are in preclinical or clinical phase 1
Changes in the pipeline of cellular immunotherapy from 2019 to 2021
Changes in the pipeline of cellular immunotherapy from 2019 to 2021CD19, BCMA, etc.
CD19, BCMA, etc.
Judging from the five products approved by the FDA, CD19 with four listed drugs and BCMA with one listed product are undoubtedly one of the hottest tracks
Popular targets in the field of hematoma
Popular targets in the field of hematomaFrom the perspective of solid tumors, the research target remains basically unchanged, and the number of undisclosed tumor-associated antigens (TAA) still tops the list
Popular targets for solid tumors
Popular targets for solid tumorsChina and the United States are leading the world in research projects, solid tumors are still difficult to treat
China and the United States are leading the world in research projects, solid tumors are still difficult to treatThe report pointed out that according to the data of ClinicalTrials.
At present, the United States is still the leader in cellular immunotherapy, with 791 cell therapy projects in progress, and China’s domestic enthusiasm for cellular immunotherapy is not inferior, with the number of projects reaching 695.
Global overview of cell therapy drugs by sponsor (academic institutions and pharmaceutical manufacturers)
Global overview of cell therapy drugs by sponsor (academic institutions and pharmaceutical manufacturers)Cancer is currently one of the hottest tracks for venture capital in the medical and health field, and cellular immunotherapy is considered one of the most promising innovative therapies to overcome tumors
Reference materials:
Reference materials:[1]https://
[1]https://